AstraZeneca
AZN
1,218 hedge funds and large institutions have $34.2B invested in AstraZeneca in 2024 Q4 according to their latest regulatory filings, with 167 funds opening new positions, 423 increasing their positions, 427 reducing their positions, and 154 closing their positions.
39% more call options, than puts
Call options by funds: $491M | Put options by funds: $354M
8% more first-time investments, than exits
New positions opened: 167 | Existing positions closed: 154
0.43% more ownership
Funds ownership: 16.15% → 16.58% (+0.43%)
1% less funds holding
Funds holding: 1,229 → 1,218 (-11)
1% less repeat investments, than reductions
Existing positions increased: 423 | Existing positions reduced: 427
13% less capital invested
Capital invested by funds: $39.1B → $34.2B (-$4.9B)
24% less funds holding in top 10
Funds holding in top 10: 17 → 13 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$313M |
| 2 |
Holocene Advisors
New York
|
+$301M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$271M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$264M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$257M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$428M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$229M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$178M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$143M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$129M |
AZN Hedge Fund Activity: Q4 2024 in Review
1,218 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q4 2024, worth a combined $34.2B — down 13% from $39.1B a quarter earlier.
Buyers outnumbered sellers: 167 funds opened new AZN positions and 154 closed out — a net gain of 13 holders — while 423 added to existing stakes and 427 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $313M. The largest seller was Capital World Investors, cutting an estimated $428M.
- 1,218 institutional investors held AstraZeneca (AZN) as of Q4 2024, down from 1,229 in Q3 2024.
- Funds reported $34.2B of AstraZeneca stock for Q4 2024, down 13% quarter-over-quarter.
- 167 funds opened new AstraZeneca positions in Q4 2024 and 154 closed out, a net change of +13 holders.
- The largest AstraZeneca buyer in Q4 2024 was Morgan Stanley, an estimated $313M added.
- The largest AstraZeneca seller in Q4 2024 was Capital World Investors, an estimated $428M sold.
Based on aggregated 13F filings for Q4 2024.